Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KZR-616 in active polymyositis or dermatomyositis
NCT04033926Phase 2Completed
- Sponsor
- Kezar Life Sciences
- Start
- Jan 2020
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of zetomipzomib in polymyositis (PM) and dermatomyositis (DM) (2 arms), sponsored by Kezar Life Sciences. Primary endpoint: Total Improvement Score at 16 weeks. Started Jan 2020; status: completed.
02
Drugs
zetomipzomib
03
Conditions
polymyositis (PM)dermatomyositis (DM)
Beyond the preview
Go deeper on NCT04033926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04033926.